



THE JOURNAL OF CLINICAL PSYCHIATRY

THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

Supplementary Material

Article Title: Cannabidiol for Treatment-Resistant Anxiety Disorders in Young People: An Open-Label Trial

Author(s): Maximus Berger, MD PhD; Emily Li, BPsychPsy; Simon Rice, PhD; Christopher G. Davey, MBBS, PhD; Aswin Ratheesh, MBBS, PhD; Sophie Adams, MBBS PhD; Henry Jackson, PhD; Sarah Hetrick, PhD; Alexandra Parker, PhD; Tim Spelman, PhD; Richard Kevin, PhD; Iain S. McGregor PhD; Patrick McGorry MBBS PhD; and G. Paul Amminger, MD, PhD

DOI Number: <https://doi.org/10.4088/JCP.21m14130>

List of Supplementary Material for the article

1. [Table 1](#) Adverse events
2. [Figure 1](#) CONSORT Diagram
3. [Figure 2](#) Mean plasma concentrations of CBD in participants who received maximum daily doses of 400mg, 600mg and 800mg, respectively.


Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary Table 1 Adverse events

	All study participants (n=31)
Adverse event	Frequency, n (%)
Fatigue	8 (25.8%)
Low mood	3 (9.7%)
Hot flushes or cold chills	3 (9.7%)
Drowsiness	2 (6.5%)
Nausea	2 (6.5%)
Diarrhoea	2 (6.5%)
Dry mouth	2 (6.5%)
Insomnia	2 (6.5%)
Increased appetite	1 (3.2%)
Decreased appetite	1 (3.2%)
Urticaria	1 (3.2%)
Concentration difficulties	1 (3.2%)
Headache	1 (3.2%)
Dizziness	1 (3.2%)
Restlessness	1 (3.2%)
GI discomfort	1 (3.2%)
Muscle twitch	1 (3.2%)
Polyuria	1 (3.2%)
Hyperhidrosis	1 (3.2%)

Supplementary Figure 1 CONSORT Diagram



Supplementary Figure 2 Mean plasma concentrations of CBD in participants who received maximum daily doses of 400mg, respectively.

